Search results for "dasatinib"

showing 3 items of 23 documents

Show me your signaling– and I’ll tell you who you are

2009

See Article, pages 725–733Cancer research and therapy have come a long way:the field started out in search of a ‘‘magic bullet” accord-ing to Paul Ehrlich’s theory, and was hoping to identifya target which was pivotal to signaling survival in trans-formed cells. Indeed, certain diseases with monocausalmutations were identified, and targeting of the muta-tional products has helped in the design of treatmentstrategies. In chronic myeloid leukemia (CML), the con-stitutive activation of the tyrosine kinase BCR-ABL ispathognomonic [1], and multiple BCR-ABL kinaseinhibitors (e.g. imatinib mesylate, dasatinib, nilotinib)have been developed and successfully used in the treat-ment of CML offering near-…

SorafenibMAPK/ERK pathwayHepatologybusiness.industryPharmacologyDasatinibImatinib mesylateNilotinibmedicineCancer researchErlotinibbusinessTyrosine kinasePI3K/AKT/mTOR pathwaymedicine.drugJournal of Hepatology
researchProduct

Stochastic dynamics of leukemic cells under an intermittent targeted therapy

2009

The evolutionary dynamics of cancerous cell populations in a model of Chronic Myeloid Leukemia (CML) is investigated in the presence of an intermittent targeted therapy. Cancer development and progression is modeled by simulating the stochastic evolution of initially healthy cells which can experience genetic mutations and modify their reproductive behavior, becoming leukemic clones. Front line therapy for the treatment of patients affected by CML is based on the administration of tyrosine kinase inhibitors, namely imatinib (Gleevec) or, more recently, dasatinib or nilotinib. Despite the fact that they represent the first example of a successful molecular targeted therapy, the development o…

Statistics and ProbabilityComplex systemsmedicine.medical_treatmentModels BiologicalPiperazinesSettore FIS/03 - Fisica Della MateriaCancer evolutionTargeted therapyLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesStochastic dynamics; Cancer evolution; Complex systemsHumansMedicineComputer SimulationStochastic dynamicMolecular Targeted TherapyProtein Kinase InhibitorsEcology Evolution Behavior and SystematicsStochastic Processesbusiness.industryApplied MathematicsMyeloid leukemiaImatinibmedicine.diseaseSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)DasatinibLeukemiaPyrimidinesImatinib mesylateNilotinibStochastic dynamics Monte Carlo simulationBenzamidesImmunologyCancer cellDisease ProgressionImatinib MesylateCancer researchbusinessmedicine.drug
researchProduct

Abstract 4372: Chronic myeloid leukemia (CML) exosomes promote angiogenesis in a Src-dependent fashion in vitro and in vivo

2012

Abstract CML is an uncontrolled proliferation of bone marrow myeloid cells driven by the constitutively active fusion product tyrosine kinase BCR/ABL. Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is newly recognized as a factor in CML progression. Exosomes, released by a broad spectrum of cells, are microvesicles that play an important role in cell-to-cell communication both in physiological and pathological conditions. The role of exosomes released by CML cells in angiogenesis is emerging; however, little is known about the mechanisms involved in this process. We first isolated and characterized exosomes released by K562 CML cells and we demonstrated thei…

Tube formationCancer Researchmedicine.medical_specialtyAngiogenesisbusiness.industryImatinibExosomeMicrovesiclesDasatinibEndocrinologyOncologyhemic and lymphatic diseasesInternal medicineCancer researchmedicinebusinessTyrosine kinasemedicine.drugProto-oncogene tyrosine-protein kinase SrcCancer Research
researchProduct